This brochure explains how emerging drug modalities such as protein degraders, RNA therapeutics, antibody–drug conjugates, next-generation peptides, and gene therapies are reshaping drug discovery. It highlights the scientific and operational complexity these modalities introduce and the limitations of siloed informatics systems. Signals One is presented as a unified, cloud-native R&D platform that enables collaboration across biology, chemistry, and pharmacology. By combining ChemDraw®, advanced data analytics, and centralized workflow management, Signals One supports end-to-end assay development, data capture, and analysis. The brochure emphasizes improved reproducibility, faster insight generation, and reduced risk, enabling teams to manage complex data types and accelerate discovery of

Join for free to read